<p>Sutro Biopharma, Inc.（纳斯达克代码：STRO - 获取免费报告）在周一市场开盘前股价跳空下跌。该股票之前收于 34.83 美元，但开盘时为 33.17 美元。Sutro Biopharma 的股票最后交易价格为 33.85 美元，成交量为 8,201 股。</p>
<p>获取 <strong>Sutro Biopharma</strong> 的提醒：</p>
<h2>华尔街分析师预测增长</h2>
<p>多家券商最近对 STRO 发布了报告。Truist Financial 在 3 月 25 日的研究报告中将 Sutro Biopharma 的评级上调至 “强力买入”。Wells Fargo &amp; Company 在 3 月 24 日的研究报告中将 Sutro Biopharma 的评级从 “持平” 上调至 “超配”，并将其股票目标价从 8.00 美元提高至 27.00 美元。Leerink Partners 在 4 月 7 日的研究报告中开始覆盖 Sutro Biopharma。他们对该股票设定了 “跑赢大盘” 的评级和 38.00 美元的目标价。Citizens Jmp 在周四的研究报告中将 Sutro Biopharma 的目标价从 35.00 美元提高至 41.00 美元，并给予该股票 “市场跑赢” 的评级。最后，HC Wainwright 在 3 月 24 日的报告中将 Sutro Biopharma 的评级从 “中性” 上调至 “买入”，并将其股票目标价从 10.00 美元提高至 28.00 美元。一位投资分析师对该股票给予了强力买入评级，七位分析师给予了买入评级，一位给予了持有评级，两位给予了卖出评级。根据 MarketBeat 的数据，该股票的平均评级为 “适度买入”，共识目标价为 39.63 美元。</p>
<p><strong>阅读我们关于 STRO 的最新报告</strong></p>
<h2>Sutro Biopharma 股票表现</h2>
<p>该股票的 50 日移动平均价格为 24.32 美元，200 日移动平均价格为 15.76 美元。该公司的市值为 5.4416 亿美元，市盈率为-1.26，贝塔值为 1.31。</p>
<h2>对 Sutro Biopharma 的对冲基金看法</h2>
<p>几家机构投资者和对冲基金最近增加或减少了对 STRO 的持股。Invesco Ltd.在第一季度将其在 Sutro Biopharma 的持股增加了 137.8%。Invesco Ltd.现在拥有 92,139 股该公司的股票，价值 60,000 美元，此前在上个季度购买了 53,390 股。AQR Capital Management LLC 在第一季度将其在 Sutro Biopharma 的持股增加了 1,052.8%。AQR Capital Management LLC 现在拥有 1,320,917 股该公司的股票，价值 859,000 美元，此前在上个季度收购了 1,206,330 股。Strs Ohio 在第一季度购买了 Sutro Biopharma 的新头寸，价值 99,000 美元。Marshall Wace LLP 在第二季度购买了 Sutro Biopharma 的新头寸，价值 166,000 美元。最后，Cerity Partners LLC 在第二季度将其在 Sutro Biopharma 的持股增加了 169.9%。Cerity Partners LLC 现在拥有 105,437 股该公司的股票，价值 75,000 美元，此前在上个季度收购了 66,372 股。机构投资者持有该公司 96.99% 的股票。</p>
<h2>Sutro Biopharma 公司简介</h2>
<p>（获取免费报告）</p>
<p>Sutro Biopharma, Inc 是一家临床阶段的生物制药公司，专注于在肿瘤学和免疫学领域发现和开发新型生物药物候选者。该公司利用其专有的无细胞蛋白合成平台 XpressCF™设计和生产复杂的多特异性蛋白，包括抗体药物偶联物、双特异性抗体和细胞因子融合蛋白。该平台能够快速生成和优化可能无法通过传统细胞表达系统实现的蛋白治疗。</p>
<p>Sutro Biopharma 成立于 2003 年，总部位于加利福尼亚州南旧金山，已建立了一条在不同临床前和临床开发阶段的免疫肿瘤候选药物管线。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更看好的五只股票超过 Sutro Biopharma</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Sutro Biopharma 吗？</h2>
<p>在你考虑 Sutro Biopharma 之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Sutro Biopharma 并不在名单上。</p>
<p>虽然 Sutro Biopharma 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

STRO

标普生物技术 ETF - SPDR

基因改革 ETF - ARK

<p>Sutro Biopharma（纳斯达克股票代码：STRO）股价从 34.83 美元跳空下跌至 33.17 美元，开盘价为 33.85 美元。分析师的评级各不相同，其中有一项强烈买入、七项买入、一项持有和两项卖出评级。价格目标各异，市场共识为 39.63 美元。机构投资者持有 96.99% 的股份，公司专注于开发肿瘤学和免疫学领域的生物药物候选药物。尽管评级为适度买入，但一些分析师建议存在更好的投资机会</p>

<p>Sutro Biopharma, Inc. (NASDAQ:STRO - Get Free Report)'s stock price gapped down before the market opened on Monday . The stock had previously closed at $34.83, but opened at $33.17. Sutro Biopharma shares last traded at $33.85, with a volume of 8,201 shares.</p>
<div class="lb-trans"><p>Sutro Biopharma, Inc.（纳斯达克代码：STRO - 获取免费报告）在周一市场开盘前股价跳空下跌。该股票之前收于 34.83 美元，但开盘时为 33.17 美元。Sutro Biopharma 的股票最后交易价格为 33.85 美元，成交量为 8,201 股。</p>
</div><p>Get <strong>Sutro Biopharma</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Sutro Biopharma</strong> 的提醒：</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>A number of brokerages recently issued reports on STRO. Truist Financial raised Sutro Biopharma to a &#34;strong-buy&#34; rating in a research report on Wednesday, March 25th. Wells Fargo &amp; Company raised Sutro Biopharma from an &#34;equal weight&#34; rating to an &#34;overweight&#34; rating and increased their price target for the stock from $8.00 to $27.00 in a research report on Tuesday, March 24th. Leerink Partners began coverage on Sutro Biopharma in a research report on Tuesday, April 7th. They set an &#34;outperform&#34; rating and a $38.00 price target on the stock. Citizens Jmp increased their price target on Sutro Biopharma from $35.00 to $41.00 and gave the stock a &#34;market outperform&#34; rating in a research report on Thursday. Finally, HC Wainwright raised shares of Sutro Biopharma from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and upped their price target for the stock from $10.00 to $28.00 in a report on Tuesday, March 24th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $39.63.</p>
<div class="lb-trans"><p>多家券商最近对 STRO 发布了报告。Truist Financial 在 3 月 25 日的研究报告中将 Sutro Biopharma 的评级上调至 “强力买入”。Wells Fargo &amp; Company 在 3 月 24 日的研究报告中将 Sutro Biopharma 的评级从 “持平” 上调至 “超配”，并将其股票目标价从 8.00 美元提高至 27.00 美元。Leerink Partners 在 4 月 7 日的研究报告中开始覆盖 Sutro Biopharma。他们对该股票设定了 “跑赢大盘” 的评级和 38.00 美元的目标价。Citizens Jmp 在周四的研究报告中将 Sutro Biopharma 的目标价从 35.00 美元提高至 41.00 美元，并给予该股票 “市场跑赢” 的评级。最后，HC Wainwright 在 3 月 24 日的报告中将 Sutro Biopharma 的评级从 “中性” 上调至 “买入”，并将其股票目标价从 10.00 美元提高至 28.00 美元。一位投资分析师对该股票给予了强力买入评级，七位分析师给予了买入评级，一位给予了持有评级，两位给予了卖出评级。根据 MarketBeat 的数据，该股票的平均评级为 “适度买入”，共识目标价为 39.63 美元。</p>
</div><p><strong>Read Our Latest Report on STRO</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 STRO 的最新报告</strong></p>
</div><h2>Sutro Biopharma Stock Performance</h2>
<div class="lb-trans"><h2>Sutro Biopharma 股票表现</h2>
</div><p>The stock's fifty day moving average price is $24.32 and its two-hundred day moving average price is $15.76. The company has a market cap of $544.16 million, a P/E ratio of -1.26 and a beta of 1.31.</p>
<div class="lb-trans"><p>该股票的 50 日移动平均价格为 24.32 美元，200 日移动平均价格为 15.76 美元。该公司的市值为 5.4416 亿美元，市盈率为-1.26，贝塔值为 1.31。</p>
</div><h2>Hedge Funds Weigh In On Sutro Biopharma</h2>
<div class="lb-trans"><h2>对 Sutro Biopharma 的对冲基金看法</h2>
</div><p>Several institutional investors and hedge funds have recently added to or reduced their stakes in STRO. Invesco Ltd. lifted its stake in Sutro Biopharma by 137.8% in the 1st quarter. Invesco Ltd. now owns 92,139 shares of the company's stock valued at $60,000 after purchasing an additional 53,390 shares during the last quarter. AQR Capital Management LLC lifted its stake in shares of Sutro Biopharma by 1,052.8% in the 1st quarter. AQR Capital Management LLC now owns 1,320,917 shares of the company's stock valued at $859,000 after acquiring an additional 1,206,330 shares during the last quarter. Strs Ohio bought a new position in shares of Sutro Biopharma in the 1st quarter valued at $99,000. Marshall Wace LLP bought a new position in shares of Sutro Biopharma in the 2nd quarter valued at $166,000. Finally, Cerity Partners LLC lifted its stake in shares of Sutro Biopharma by 169.9% in the 2nd quarter. Cerity Partners LLC now owns 105,437 shares of the company's stock valued at $75,000 after acquiring an additional 66,372 shares during the last quarter. Institutional investors own 96.99% of the company's stock.</p>
<div class="lb-trans"><p>几家机构投资者和对冲基金最近增加或减少了对 STRO 的持股。Invesco Ltd.在第一季度将其在 Sutro Biopharma 的持股增加了 137.8%。Invesco Ltd.现在拥有 92,139 股该公司的股票，价值 60,000 美元，此前在上个季度购买了 53,390 股。AQR Capital Management LLC 在第一季度将其在 Sutro Biopharma 的持股增加了 1,052.8%。AQR Capital Management LLC 现在拥有 1,320,917 股该公司的股票，价值 859,000 美元，此前在上个季度收购了 1,206,330 股。Strs Ohio 在第一季度购买了 Sutro Biopharma 的新头寸，价值 99,000 美元。Marshall Wace LLP 在第二季度购买了 Sutro Biopharma 的新头寸，价值 166,000 美元。最后，Cerity Partners LLC 在第二季度将其在 Sutro Biopharma 的持股增加了 169.9%。Cerity Partners LLC 现在拥有 105,437 股该公司的股票，价值 75,000 美元，此前在上个季度收购了 66,372 股。机构投资者持有该公司 96.99% 的股票。</p>
</div><h2>Sutro Biopharma Company Profile</h2>
<div class="lb-trans"><h2>Sutro Biopharma 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.</p>
<div class="lb-trans"><p>Sutro Biopharma, Inc 是一家临床阶段的生物制药公司，专注于在肿瘤学和免疫学领域发现和开发新型生物药物候选者。该公司利用其专有的无细胞蛋白合成平台 XpressCF™设计和生产复杂的多特异性蛋白，包括抗体药物偶联物、双特异性抗体和细胞因子融合蛋白。该平台能够快速生成和优化可能无法通过传统细胞表达系统实现的蛋白治疗。</p>
</div><p>Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.</p>
<div class="lb-trans"><p>Sutro Biopharma 成立于 2003 年，总部位于加利福尼亚州南旧金山，已建立了一条在不同临床前和临床开发阶段的免疫肿瘤候选药物管线。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Sutro Biopharma</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过 Sutro Biopharma</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Sutro Biopharma Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Sutro Biopharma 吗？</h2>
</div><p>Before you consider Sutro Biopharma, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Sutro Biopharma 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sutro Biopharma wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Sutro Biopharma 并不在名单上。</p>
</div><p>While Sutro Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Sutro Biopharma 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Sutro Biopharma (NASDAQ:STRO) Shares Gap Down   - What's Next?

Market Beat

Sutro Biopharma

生物科技 ETF - VanEck Vectors

医药突破 ETF - ALPS

纽交所高增长板生物技术指数 ETF - First Trust

Invesco Nasdaq Biotechnology ETF

纳斯达克生物科技指数 ETF - iShares Nasdaq

2 倍做多纳斯达克生物技术 ETF - ProShares

标普生物技术 3 倍做多 - Direxion

动态生物技术与基因组 ETF - Invesco

Sutro Biopharma（纳斯达克代码：STRO）股价跳空下跌 - 接下来会如何发展？